IL-13 Targeting Biologics for the Treatment of Atopic Dermatitis : Episode 8

Opinion

Video

February 4, 2025

Efficacy Data With IL-13 Targeting Agents in Atopic Dermatitis

Panelists provide an overview of the latest efficacy and safety data for IL-13–targeting therapies in atopic dermatitis (AD), including recently presented data on dupilumab, lebrikizumab, and tralokinumab, focusing on their effectiveness in symptom reduction and safety profiles across patient populations.

EP: 1.Heterogenous Presentation Of Atopic Dermatitis

EP: 2.Use of Biopsy and Diagnosing New-Onset AD

EP: 3.Treatment Options in Atopic Dermatitis

EP: 4.Improvement in Standard of Care in Atopic Dermatitis

EP: 5.Improvement in Patients’ Qualify of Life with Atopic Dermatitis Treatments

EP: 6.Guidance for Moving to Advanced Systemic Therapy and Biologic Agents

EP: 7.IL-13–Targeting Agents in Atopic dermatitis

EP: 8.Efficacy Data With IL-13 Targeting Agents in Atopic Dermatitis

Video content above is prompted by the following:

Please give an overview of latest efficacy and safety data with IL-13–targeting therapies in AD, including recently presented data.
Dupilumab
Lebrikizumab
Tralokinumab

Related Videos

Greg A. Sachs, MD I Credit: Regenstrief Institute

3 experts are featured in this series.

Pranav Garimella, MBBS, MPH | Credit: GlobalNewsWire

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.